Gomez Zuleta MA. Colon cancer screening: What to choose? World J Gastrointest Oncol 2024; 16(8): 3393-3396 [PMID: 39171178 DOI: 10.4251/wjgo.v16.i8.3393]
Corresponding Author of This Article
Martin Alonso Gomez Zuleta, Doctor, MD, Associate Professor, Department of Internal Medicine, Head of Gastroenterology Unit, Universidad Nacional de Colombia, Hospital Universitario Nacional de Colombi, 18 Carrera, 124-26, Bogota 571, Colombia. martinalonsogomezz@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3393-3396 Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3393
Colon cancer screening: What to choose?
Martin Alonso Gomez Zuleta
Martin Alonso Gomez Zuleta, Department of Internal Medicine, Head of Gastroenterology Unit, Universidad Nacional de Colombia, Hospital Universitario Nacional de Colombi, Bogota 571, Colombia
Author contributions: Gomez Zuleta MA is the single author, design and wrote the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Martin Alonso Gomez Zuleta, Doctor, MD, Associate Professor, Department of Internal Medicine, Head of Gastroenterology Unit, Universidad Nacional de Colombia, Hospital Universitario Nacional de Colombi, 18 Carrera, 124-26, Bogota 571, Colombia. martinalonsogomezz@gmail.com
Received: April 6, 2024 Revised: May 11, 2024 Accepted: May 24, 2024 Published online: August 15, 2024 Processing time: 123 Days and 7.1 Hours
Abstract
Colorectal cancer is one of the predominant tumors in the world, primarily generated by a progression from polyp to cancer which can last several years, giving a great opportunity to the scientific community for its prevention by screening programs that can be done with invasive and non-invasive tests. In this issue, Lopes et al show us an excellent review of screening, its options, its advantages and disadvantages.
Core Tip: Colorectal cancer can be prevented in more than 90% of cases, but for this it is very important to have screening programs that detect and treat the disease in time. Although there are multiple tests and probably non-invasive serological tests will be the ones used in the future. Two tests are mainly used on a regular basis in the world: Fecal immunochemical test and colonoscopy and we should focus our attention on them when deciding. In this editorial we will discuss these aspects.
